Brazilian health regulator Anvisa will no longer require vaccines used by the UN-backed COVAX facility to file requests for emergency approval. Brazil is expected to receive 10.6 million of the 42 million doses it is entitled to in the first half of the year, mainly from AstraZeneca.
The decision may help speed up the immunization process, as India’s Serum Institute — which has provided the first 2 million doses of the AstraZeneca vaccine — would otherwise have to file for emergency use requests in Brazil.
Support this coverage →
Search
